



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Mail Stop Sequence  
Commissioner-for-Patents

P.O. Box 1450  
Alexandria, VA 22313-1450

On 11 Dec. 2003

TOWNSEND and TOWNSEND and CREW LLP

By: Malinda A. Dagit

PATENT

Attorney Docket No.: 015280-325200US  
Client Ref. No.: E-157-1997/0-US-08  
Customer No.: 20350

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

RYBACK *et al.*

Application No.: 09/918,887

Filed: July 30, 2001

For: IMMUNOTOXINS DIRECTED  
AGAINST MALIGNANT CELLS

Customer No.: 20350

Confirmation No. 54276

Examiner: Schwadron, Ronald B.

Technology Center/Art Unit: 1644

COMMUNICATION UNDER 37 C.F.R. §§  
1.821-1.825 AND AMENDMENT

Mail Stop Sequence  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Office Communication mailed December 4, 2003, Applicants submit herewith the required corrected paper copy of the Substitute Sequence Listing, along with a copy of the computer readable form.

The **Amendments to the Specification** begin on page 2 of this paper.

**Remarks** begin on page 3 of this paper.